These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 18599033

  • 1. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
    Gunnet JW, Wines P, Xiang M, Rybczynski P, Andrade-Gordon P, de Garavilla L, Parry TJ, Cheung WM, Minor L, Demarest KT, Maryanoff BE, Damiano BP.
    Eur J Pharmacol; 2008 Aug 20; 590(1-3):333-42. PubMed ID: 18599033
    [Abstract] [Full Text] [Related]

  • 2. Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.
    Gunnet JW, Matthews JM, Maryanoff BE, de Garavilla L, Andrade-Gordon P, Damiano B, Hageman W, Look R, Stahle P, Streeter AJ, Wines PG, Demarest KT.
    Clin Exp Pharmacol Physiol; 2006 Apr 20; 33(4):320-6. PubMed ID: 16620295
    [Abstract] [Full Text] [Related]

  • 3. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T.
    J Pharmacol Exp Ther; 1998 Dec 20; 287(3):860-7. PubMed ID: 9864265
    [Abstract] [Full Text] [Related]

  • 4. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.
    Cardiovasc Drug Rev; 2007 Dec 20; 25(1):1-13. PubMed ID: 17445084
    [Abstract] [Full Text] [Related]

  • 5. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
    Nakamura S, Yamamura Y, Itoh S, Hirano T, Tsujimae K, Aoyama M, Kondo K, Ogawa H, Shinohara T, Kan K, Tanada Y, Teramoto S, Sumida T, Nakayama S, Sekiguchi K, Kambe T, Tsujimoto G, Mori T, Tominaga M.
    Br J Pharmacol; 2000 Apr 20; 129(8):1700-6. PubMed ID: 10780976
    [Abstract] [Full Text] [Related]

  • 6. Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.
    Xiang MA, Rybczynski PJ, Patel M, Chen RH, McComsey DF, Zhang HC, Gunnet JW, Look R, Wang Y, Minor LK, Zhong HM, Villani FJ, Demarest KT, Damiano BP, Maryanoff BE.
    Bioorg Med Chem Lett; 2007 Dec 01; 17(23):6623-8. PubMed ID: 17942308
    [Abstract] [Full Text] [Related]

  • 7. In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V(1A) receptor antagonist 4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl-(3,5-difluoro-phenyl) methanone (PF-00738245).
    Russell R, Doyle R, Turner J, Attkins N, Ramsey S, Weibley L, Bateman L, Bictash M, Neal-Morgan S, Ivarsson M, Pullen N.
    Eur J Pharmacol; 2011 Nov 30; 670(2-3):347-55. PubMed ID: 21958878
    [Abstract] [Full Text] [Related]

  • 8. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D, Jard S, Vilain P, Garcia C, Marty E, Raufaste D, Brossard G, Nisato D, Maffrand JP, Le Fur G.
    J Clin Invest; 1996 Dec 15; 98(12):2729-38. PubMed ID: 8981918
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.
    Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, Tariga H, Alagarsamy S, Ly B, Dykert J, Qi S, Wisniewski K, Galyean R, Croston G, Schteingart CD, Rivière PJ.
    J Pharmacol Exp Ther; 2011 Jun 15; 337(3):786-96. PubMed ID: 21411496
    [Abstract] [Full Text] [Related]

  • 10. Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy.
    Tahara A, Tsukada J, Tomura Y, Suzuki T, Yatsu T, Shibasaki M.
    Vascul Pharmacol; 2007 Jun 15; 46(6):463-9. PubMed ID: 17395547
    [Abstract] [Full Text] [Related]

  • 11. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M.
    J Pept Sci; 2006 Mar 15; 12(3):190-8. PubMed ID: 16130178
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.
    Tahara A, Tomura Y, Wada KI, Kusayama T, Tsukada J, Takanashi M, Yatsu T, Uchida W, Tanaka A.
    J Pharmacol Exp Ther; 1997 Jul 15; 282(1):301-8. PubMed ID: 9223568
    [Abstract] [Full Text] [Related]

  • 13. Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.
    Tsukada J, Tahara A, Tomura Y, Wada Ki, Kusayama T, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A.
    Br J Pharmacol; 2001 Jul 15; 133(5):746-54. PubMed ID: 11429400
    [Abstract] [Full Text] [Related]

  • 14. Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells.
    Tahara A, Tsukada J, Tomura Y, Momose K, Suzuki T, Yatsu T, Shibasaki M.
    Eur J Pharmacol; 2006 May 24; 538(1-3):32-8. PubMed ID: 16678155
    [Abstract] [Full Text] [Related]

  • 15. Age-dependent regulation of renal vasopressin V(1A) and V₂ receptors in rats with genetic hypertension: implications for the treatment of hypertension.
    Burrell LM, Risvanis J, Dean RG, Patel SK, Velkoska E, Johnston CI.
    J Am Soc Hypertens; 2013 May 24; 7(1):3-13. PubMed ID: 23246465
    [Abstract] [Full Text] [Related]

  • 16. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
    Nakamura S, Hirano T, Tsujimae K, Aoyama M, Kondo K, Yamamura Y, Mori T, Tominaga M.
    J Pharmacol Exp Ther; 2000 Dec 24; 295(3):1005-11. PubMed ID: 11082435
    [Abstract] [Full Text] [Related]

  • 17. Vasopressin and angiotensin receptors of the medial septal area in the control of mean arterial pressure induced by vasopressin.
    Pavan de Arruda Camargo GM, Abrão Saad W, de Arruda Camargo LA.
    J Renin Angiotensin Aldosterone Syst; 2008 Sep 24; 9(3):133-8. PubMed ID: 18957383
    [Abstract] [Full Text] [Related]

  • 18. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Sep 24; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 19. Age-dependent regulation of vasopressin V1a receptors in preglomerular vessels from the spontaneously hypertensive rat.
    Vågnes B ØB, Hansen FH, Christiansen RE, Gjerstad C, Iversen BM.
    Am J Physiol Renal Physiol; 2004 May 24; 286(5):F997-1003. PubMed ID: 15075196
    [Abstract] [Full Text] [Related]

  • 20. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
    Tahara A, Tsukada J, Tomura Y, Kusayama T, Wada K, Ishii N, Taniguchi N, Suzuki T, Yatsu T, Uchida W, Shibasaki M.
    Pharmacol Res; 2005 Mar 24; 51(3):275-81. PubMed ID: 15661579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.